There is no mechanism to purchase shares directly from Acerus.

The declaration and payment of dividends on the Acerus Common Shares is at the discretion of the Corporation’s board of directors. It is the board of directors’ present policy to retain its earnings to finance growth, fund future development projects and expand its operations. As such, it does not anticipate paying any dividends in the foreseeable future.

Acerus is currently reporting in U.S. Dollars.

Acerus trades on the Toronto Stock Exchange under the ticker “ASP”. Acerus also trades on the OTCQB Exchange in the Unites States under the ticker “ASPCF”.

Acerus’ year-end is December 31.

Acerus was incorporated under the Business Corporations Act (Ontario) on July 15, 2009 as J5 Acquisition Corp. (“J5”). From incorporation until July 11, 2011, when J5 amended its articles of incorporation to change its name to “Trimel Pharmaceuticals Corporation”, the Corporation operated as a “capital pool company” (“CPC”) pursuant to Policy 2.4 of the TSX Venture Exchange (“TSX-V”) Corporate Finance Manual. On July 14, 2011, J5 (Barbados), Inc., a wholly-owned subsidiary of J5 incorporated under Barbados law, amalgamated with Trimel BioPharma Holdings Inc. (“Trimel Holdings”) under the name “Trimel BioPharma Holdings Inc.” Upon completion of the amalgamation, the Corporation completed its qualifying transaction (“the Qualifying Transaction”) by way of a reverse takeover transaction through an exchange of shares, resulting in the former shareholders of Trimel Holdings obtaining control of the Corporation and acquiring 100% of the common shares of the Corporation. On September 8, 2015, the name of the Corporation was formally changed from “Trimel Pharmaceuticals Corporation” to “Acerus Pharmaceuticals Corporation”.

On July 19, 2011, the Corporation’s common shares were delisted from the TSX-V and graduated and listed for trading on the Toronto Stock Exchange (the “TSX”) under the symbol “TRL”. Concurrent with the change of corporate name in September 2015, the trading symbol of the Acerus Common Shares on the TSX was changed to “ASP”.

These filings are available on this page above and on the SEDAR website at www.sedar.com.

Investors are invited to contact the Company’s Transfer Agent, TSX Trust Company, with general questions about their shareholdings, including the loss of share certificates or a change of address.

TSX Trust Company can be reached using the following methods:
Phone: +1 (416) 342-1091 or toll free on 1 866 600 5869
E-mail: tmxeinvestorservices@tmx.com

Acerus’ current auditor is PricewaterhouseCoopers LLP.